Keywords: novo, nordisk, 1st, half, allays, fears, denmark
Novo Nordisk 1st half allays fears
Article | 12 August 2002
Denmark's Novo Nordisk has posted turnover of 12.0 billion Danishkroner ($1.63 billion) for first-half 2002, an increase of 6% on the like, 2001 period; in ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
